Rosa S Djajadiningrat1, Simon Horenblas1, Daniëlle A M Heideman2, Joyce Sanders3, Jeroen de Jong3, Ekaterina S Jordanova4. 1. Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 2. Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands. 3. Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 4. Centre for Gynaecologic Oncology Amsterdam, VU University Medical Center, Amsterdam, The Netherlands. Electronic address: e.jordanova@vumc.nl.
Abstract
PURPOSE: Loss of expression of HLA class I is a mechanism of immune evasion in various cancers that is often associated with a worse patient outcome. We analyzed HLA expression in a large cohort with penile cancer in relation to clinical outcome. MATERIALS AND METHODS: We used penile cancer tissue blocks from 168 patients who underwent surgical resection between 2000 and 2009 to construct tissue microarrays. Immunohistochemical staining was done with antibodies directed against classic and nonclassic HLA molecules. HLA expression was scored semiquantitatively, divided into 3 expression groups and correlated with clinicopathological variables, including HPV and survival. Survival analysis was performed using the Kaplan-Meier method and Cox proportional hazards models. RESULTS: Complete and partial loss of total classic HLA class I was observed in 32% and 50% of cases, and up-regulation of HLA-E and G in 16% and 13%, respectively. When corrected for relevant clinical parameters, partial HLA-A loss was significantly associated with decreased survival overall (HR 2.3, 95% CI 1.1-4.6) and in HPV negative patients alone (HR 3.4, 95% CI 1.4-8.4). Abnormal HLA-B/C, E or G expression levels were not associated with survival. CONCLUSIONS: To our knowledge this is the first study to describe a link between HLA expression and the clinical outcome of penile cancer. HLA down-regulation occurs frequently and partial loss of HLA-A is an independent predictor of poor survival in HPV negative patients. Complete understanding of the mechanisms and relevance of HLA down-regulation and immune evasion in regard to the clinical outcome will contribute to the future design of immunotherapy interventions.
PURPOSE: Loss of expression of HLA class I is a mechanism of immune evasion in various cancers that is often associated with a worse patient outcome. We analyzed HLA expression in a large cohort with penile cancer in relation to clinical outcome. MATERIALS AND METHODS: We used penile cancer tissue blocks from 168 patients who underwent surgical resection between 2000 and 2009 to construct tissue microarrays. Immunohistochemical staining was done with antibodies directed against classic and nonclassic HLA molecules. HLA expression was scored semiquantitatively, divided into 3 expression groups and correlated with clinicopathological variables, including HPV and survival. Survival analysis was performed using the Kaplan-Meier method and Cox proportional hazards models. RESULTS: Complete and partial loss of total classic HLA class I was observed in 32% and 50% of cases, and up-regulation of HLA-E and G in 16% and 13%, respectively. When corrected for relevant clinical parameters, partial HLA-A loss was significantly associated with decreased survival overall (HR 2.3, 95% CI 1.1-4.6) and in HPV negative patients alone (HR 3.4, 95% CI 1.4-8.4). Abnormal HLA-B/C, E or G expression levels were not associated with survival. CONCLUSIONS: To our knowledge this is the first study to describe a link between HLA expression and the clinical outcome of penile cancer. HLA down-regulation occurs frequently and partial loss of HLA-A is an independent predictor of poor survival in HPV negative patients. Complete understanding of the mechanisms and relevance of HLA down-regulation and immune evasion in regard to the clinical outcome will contribute to the future design of immunotherapy interventions.
Authors: Sayuri Yoshihama; Jason Roszik; Isaac Downs; Torsten B Meissner; Saptha Vijayan; Bjoern Chapuy; Tabasum Sidiq; Margaret A Shipp; Gregory A Lizee; Koichi S Kobayashi Journal: Proc Natl Acad Sci U S A Date: 2016-05-09 Impact factor: 11.205
Authors: Debbie M Ferns; A Marijne Heeren; Sanne Samuels; Maaike C G Bleeker; Tanja D de Gruijl; Gemma G Kenter; Ekaterina S Jordanova Journal: J Immunother Cancer Date: 2016-11-15 Impact factor: 13.751
Authors: Carlo Buonerba; Giuseppe Di Lorenzo; Giuseppe Calderoni; Matteo Ferro; Francesco Perri; Lucia Lombardi; Raffaele Ardito; Piera Federico; Sabino De Placido; Michele Aieta Journal: Future Sci OA Date: 2015-11-01
Authors: Sarah Rosanne Ottenhof; Rosa Sanne Djajadiningrat; Helene Hoegsbro Thygesen; Pamela Josephine Jakobs; Katarzyna Jóźwiak; Anne Marijne Heeren; Jeroen de Jong; Joyce Sanders; Simon Horenblas; Ekaterina Straschimirova Jordanova Journal: Front Immunol Date: 2018-06-11 Impact factor: 7.561
Authors: Steven F Gameiro; Ali Zhang; Farhad Ghasemi; John W Barrett; Anthony C Nichols; Joe S Mymryk Journal: Viruses Date: 2017-09-10 Impact factor: 5.048